A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Bosutinib trial in First line chrOnic myelogenous leukemia tREatment; BFORE)
A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Bosutinib trial in First line chrOnic myelogenous leukemia tREatment; BFORE). A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.
Category & Conditions: Cancer
Medicine: BOSULIF®(BOSUTINIB)
ClinicalTrials.gov Identifier (NCT): NCT02130557
Protocol ID: B1871053
PrintDownloadOpen Plain Language Summary Result: Click here